Latest Impairment News

ARB Corporation’s half-year results reveal a modest sales dip driven by Australian OEM challenges, while robust US export growth offers a silver lining.

James Hardie Industries is set to close its Fontana and Summerville manufacturing plants, consolidating production to boost efficiency and cut costs by $25 million annually starting next fiscal year.

Endeavour Group reports modest sales growth in the first half of FY26, driven by strong momentum at Dan Murphy’s and BWS, despite retail margin compression from price investments. Significant one-off costs related to warehouse changes weigh on profits.

Neuren Pharmaceuticals has published promising Phase 2 trial results for NNZ-2591 in Phelan-McDermid syndrome, underpinning its ongoing Phase 3 Koala trial recruiting in the US.

Central Petroleum has amended its sub-salt exploration permit sale, excluding the EP82 permit and retaining Helium Australia Pty Ltd, while anticipating a $4.2 million impairment charge in FY26.

nib holdings limited signals higher-than-expected non-recurring expenses in the first half of 2026, impacting statutory profit but leaving underlying performance steady.

Actinogen Medical has finalized enrollment and begun treatment of all 246 participants in its XanaMIA Phase 2b/3 Alzheimer’s trial, with topline results expected in November 2026. The oral drug Xanamem targets brain cortisol to potentially slow disease progression.

Locality Planning Energy Holdings has reached a confidential settlement over its Harbour Towers dispute, anticipating a net gain and cash inflow in FY2026. This resolution reverses prior impairment losses and signals a positive financial turn for the embedded energy provider.

Sequoia Financial Group reports a 15% rise in EBITDA year-to-date November 2025 despite legacy claim settlements and expected impairments, while its APAC expansion gains momentum.

Neurizon Therapeutics has secured FDA clearance for its lead drug candidate NUZ-001 to enter the HEALEY ALS Platform Trial, marking a key regulatory milestone and setting the stage for patient enrollment in early 2026.

Bapcor Limited has revised its first-half FY26 guidance to a statutory net loss, citing weaker trade segment performance and one-off costs, while maintaining a cautiously optimistic full-year outlook supported by cost savings and leadership changes.

Neurizon Therapeutics has completed manufacturing three GMP registration batches of its lead ALS drug candidate NUZ-001 ahead of schedule, paving the way for FDA submissions and clinical trial enrollment.